Trials / Terminated
TerminatedNCT00885963
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Cyclacel Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase II study to evaluate the safety and efficacy of oral sapacitabine in previously treated advanced non-small cell lung cancer (NSCLC).
Detailed description
This is an open label, single arm, phase II study to evaluate the safety and efficacy of oral sapacitabine administered twice daily for 5 consecutive days every week for 2 weeks followed by 7-day rest in patients who have had one prior chemotherapy regimen for advanced Non-Small Cell Lung Cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sapacitabine | twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2013-08-13
- Completion
- 2013-12-23
- First posted
- 2009-04-22
- Last updated
- 2021-12-22
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00885963. Inclusion in this directory is not an endorsement.